icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
 
 
 
Adherence to Prescribed Doses of ABT-450/r/Ombitasvir, Dasabuvir, and Ribavirin in the Phase 3 PEARL-II, PEARL-III, and PEARL-IV Trials
 
 
  Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
 
David Bernstein1, Rui T Marinho2, Daniel E Cohen3, Fritz Bredeek4, Ferenc Schneider5, Gunnar Norkrans6, Manuela Curescu7, Michael Bennett 8, Marina Maevskaya9, Jeff rey Fessel10, Wangang Xie3, Yan Luo3, Jeff rey V Enejosa3 1Hofstra North Shore-LIJ School of Medicine, Manhasset, New York, United States; 2Centro Hospitalar Lisboa Norte, Medical School of Lisbon, Lisbon, Portugal; 3AbbVie Inc., North Chicago, Illinois, United States; 4Metropolis Medical Group, San Francisco, California, United States; 5Markusovszky Hospital, Szombathely, Hungary;
6Sahlgrenska University Hospital, Goteborg, Sweden; 7Life Search SRL, Timisoara, Romania; 8Medical Associates Research Group, San Diego, California, United States; 9First Moscow State Medical Universita naIM Sechenov, Moscow, Russia; 10Kaiser Permanente, San Francisco, California, United States

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif